...
  • Apple, Inc AAPL
  • S&P 500 ETF Trust SPDR SPY
  • Alphabet Inc. - Class A Shares GOOGL
  • Microsoft Corporation MSFT
  • Meta Platforms Inc META
  • Netflix, Inc. NFLX
  • Amazon.com Inc. AMZN
  • Spotify Technology SA SPOT
    vktx-img

    Viking Therapeutics Inc, Common Stock

    VKTX

    NAQ

    $69.06

    -$8.95

    (-11.47%)

    1D
    Industry: Biotechnology Sector: Health Care

    Analyst Forecast

    Overview Returns Financials Ratios News FAQs

    Price Chart

    Key Metrics

    Market Cap info-icon
    This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
     $7.62B
    P/E Ratio info-icon
    This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
     0
    Volume info-icon
    This is the total number of shares traded during the most recent trading day.
     7.49M
    Avg Volume info-icon
    This is the average number of shares traded during the most recent 30 days.
     2.89M
    Dividend Yield info-icon
    This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
     0.00%
    Beta info-icon
    This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
     1.12
    52-week Range info-icon
    This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
    $8.28 L
    $99.41 H
    $69.06

    About Viking Therapeutics Inc, Common Stock

    Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. more

    Industry: BiotechnologySector: Health Care

    Returns

    Time FrameVKTXSectorS&P500
    1-Week Return-13.89%2.02%1.83%
    1-Month Return1.63%5.42%5.21%
    3-Month Return90.77%0.76%6.41%
    6-Month Return555.84%14.69%18.56%
    1-Year Return180.22%13.56%31.13%
    3-Year Return1035.86%24.33%33.46%
    5-Year Return714.39%79.82%100.15%
    10-Year Return670.76%195.43%239.34%

    Financials

    Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
    Total Revenue-10.73K10.70K--[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.72,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
    Cost of Revenue260.00K277.00K296.00K291.00K292.00K[{"date":"2019-12-31","value":87.84,"profit":true},{"date":"2020-12-31","value":93.58,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.31,"profit":true},{"date":"2023-12-31","value":98.65,"profit":true}]
    Gross Profit(260.00K)10.73K(296.00K)(291.00K)(292.00K)[{"date":"2019-12-31","value":-2422.89,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-2758.36,"profit":false},{"date":"2022-12-31","value":-2711.77,"profit":false},{"date":"2023-12-31","value":-2721.09,"profit":false}]
    Gross Margin-100.00%(2766.10%)--[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-2766.1,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
    Operating Expenses32.69M42.66M55.68M70.36M100.83M[{"date":"2019-12-31","value":32.42,"profit":true},{"date":"2020-12-31","value":42.31,"profit":true},{"date":"2021-12-31","value":55.23,"profit":true},{"date":"2022-12-31","value":69.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
    Operating Income(32.69M)(42.66M)(55.68M)(70.36M)(100.83M)[{"date":"2019-12-31","value":-3268700000,"profit":false},{"date":"2020-12-31","value":-4266200000,"profit":false},{"date":"2021-12-31","value":-5568200000,"profit":false},{"date":"2022-12-31","value":-7035500000,"profit":false},{"date":"2023-12-31","value":-10082700000,"profit":false}]
    Total Non-Operating Income/Expense13.81M45.75M1.38M3.02M25.91M[{"date":"2019-12-31","value":30.19,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":3.01,"profit":true},{"date":"2022-12-31","value":6.6,"profit":true},{"date":"2023-12-31","value":56.63,"profit":true}]
    Pre-Tax Income(25.78M)(39.49M)(54.99M)(68.87M)(85.89M)[{"date":"2019-12-31","value":-2577900000,"profit":false},{"date":"2020-12-31","value":-3949500000,"profit":false},{"date":"2021-12-31","value":-5499000000,"profit":false},{"date":"2022-12-31","value":-6886700000,"profit":false},{"date":"2023-12-31","value":-8589500000,"profit":false}]
    Income Taxes(4.00K)(3.48M)(988.00K)(1.49M)-[{"date":"2019-12-31","value":-400000,"profit":false},{"date":"2020-12-31","value":-348400000,"profit":false},{"date":"2021-12-31","value":-98800000,"profit":false},{"date":"2022-12-31","value":-148800000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
    Income After Taxes(25.77M)(36.01M)(54.00M)(67.38M)-[{"date":"2019-12-31","value":-2577500000,"profit":false},{"date":"2020-12-31","value":-3601100000,"profit":false},{"date":"2021-12-31","value":-5400200000,"profit":false},{"date":"2022-12-31","value":-6737900000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
    Income From Continuous Operations(25.78M)(39.49M)(54.99M)(69.13M)(80.85M)[{"date":"2019-12-31","value":-2577900000,"profit":false},{"date":"2020-12-31","value":-3949500000,"profit":false},{"date":"2021-12-31","value":-5499000000,"profit":false},{"date":"2022-12-31","value":-6912500000,"profit":false},{"date":"2023-12-31","value":-8084900000,"profit":false}]
    Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
    Net Income(25.78M)(39.49M)(54.00M)(67.38M)(85.89M)[{"date":"2019-12-31","value":-2577900000,"profit":false},{"date":"2020-12-31","value":-3949500000,"profit":false},{"date":"2021-12-31","value":-5400200000,"profit":false},{"date":"2022-12-31","value":-6737900000,"profit":false},{"date":"2023-12-31","value":-8589500000,"profit":false}]
    EPS (Diluted)(0.36)(0.54)(0.72)(0.91)(0.92)[{"date":"2019-12-31","value":-36,"profit":false},{"date":"2020-12-31","value":-54,"profit":false},{"date":"2021-12-31","value":-72,"profit":false},{"date":"2022-12-31","value":-91,"profit":false},{"date":"2023-12-31","value":-92,"profit":false}]

    Ratios

    Liquidity

    These ratios help you determine the liquidity of the company. Higher is better.

    VKTX
    Cash Ratio 29.38
    Current Ratio 29.48

    Asset Efficiency

    These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

    VKTX
    ROA (LTM) -12.78%
    ROE (LTM) -17.55%

    Liabilities

    These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

    VKTX
    Debt Ratio Lower is generally better. Negative is bad. 0.03
    Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.97

    Valuation

    These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

    VKTX
    Trailing PE NM
    Forward PE NM
    P/S (TTM) 0.00
    P/B 21.71
    Price/FCF NM
    EV/R 0.00
    EV/Ebitda NM

    News

    Tiny but Mighty: 3 Small-Cap Stocks Crushing the Russell 2000

    The mega-cap tech stocks have garnered much attention in recent months. However, certain smaller companies have also performed well, with some small-cap stocks to buy showing promise for growth. In fact, several small-cap stocks have outperformed the large-caps that typically steal headlines. Some have even logged triple-digit price increases this year and are still good candidates for small-cap stocks to buy. While larger cap stocks have performed well amid a narrowing market, analysts suggest some small-cap stocks to buy may see increased growth as the market broadens. Generally, small-cap stocks tend to be more adaptable to changing economic conditions. As such, individual small-cap stocks offer higher growth potential and often outpace the S&P 500 over the long term. However, this implies these small-cap stocks to buy typically come with higher risk due to greater volatility. The following small-cap stocks to buy have been crushing it on the Russell 2000 and have the potential to keep momentum going while beating the Magnificent Seven: Viking Therapeutics (VKTX) Source: shutterstock.com/Romix Image One of the small-cap stocks to buy is Viking Therapeutics (NASDAQ: VKTX ).

    16 May, 2024 a 11:00 am InvestorPlace

    How Viking Therapeutics Stock Could 30x

    This mid-cap biopharma may one day be a titan of the industry.

    13 May, 2024 a 2:00 pm The Motley Fool

    Is Viking Therapeutics the Best Biotech Stock for You?

    With good mid-stage results and plenty of cash, Viking could be a winner.

    13 May, 2024 a 12:15 pm The Motley Fool

    The 3 Best Russell 2000 Stocks to Buy in May 2024

    Investing in Russell 2000 stocks is a smart idea because it focuses on small-cap stocks with substantial growth potential. While individual stocks within the index vary, some are poised to offer significant gains. Additionally, with some expectations of easing inflation and interest rates, now may be an opportune time to find the best Russell 2000 stocks to buy for potential returns. The index provides an extensive view of smaller companies, offering investors exposure to a broader segment of the market beyond large-cap stocks, which can add to portfolio diversification and bring growth prospects. These three companies are the three best stocks in the Russell 2000 to buy . If you want to invest in small-cap stocks, it makes more sense to choose the companies that will deliver better profits and growth rather than the entire index, which will provide slower returns. These are the three best Russell 2000 stocks to buy that can bring you those high returns. Celsius Holdings (CELH) Source: The Image Party / Shutterstock Celsius Holdings (NASDAQ: CELH ) develops and sells energy drinks and liquid supplements.

    10 May, 2024 a 10:55 am InvestorPlace

    7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025

    Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ). GLP-1 receptor agonist drugs commercialized by those firms have started a revolution in weight loss. The early stages of that revolution caused the share prices of those already well established firms to double. Forecasts suggest that there is plenty of growth remaining in each. Thus, there is plenty of logic behind the decision to invest in Eli Lilly and Novo Nordisk at this point. However, this article will focus on neither of those respective firms. Instead, we will dive into weight loss drug news related to seven other companies, each of which has explosive potential. Weight Loss Drug Stocks: Amgen (AMGN) Source: Shutterstock Amgen (NASDAQ: AMGN ) stock is sending ripples of fear across the pharmaceutical sector. Well, at least for those invested in Eli Lilly and Novo Nordisk. The reason Amgen is rising is that initial data related to its weight loss injection is proving positive.

    9 May, 2024 a 2:34 pm InvestorPlace

    Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly''s weight loss drug dominance

    Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

    7 May, 2024 a 3:33 pm CNBC

    Discover more

    Tsla

    Tesla, Inc.
    aaple

    Apple, Inc.
    GOOGL

    Alphabet Inc. - Class A Shares
    META

    Meta Platforms Inc
    AMZN

    Amazon.com Inc.
    Microsoft

    Microsoft Corporation
    NVDA

    NVIDIA Corporation
    BRK

    Berkshire Hathaway Inc. Hld B
    LLY

    Eli Lilly and Company

    FAQs

    What is Viking Therapeutics Inc share price today?

    Viking Therapeutics Inc (VKTX) share price today is $69.06

    Can Indians buy Viking Therapeutics Inc shares?

    Yes, Indians can buy shares of Viking Therapeutics Inc (VKTX) on Vested. To buy Viking Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VKTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

    Can Fractional shares of Viking Therapeutics Inc be purchased?

    Yes, you can purchase fractional shares of Viking Therapeutics Inc (VKTX) via the Vested app. You can start investing in Viking Therapeutics Inc (VKTX) with a minimum investment of $1.

    How to invest in Viking Therapeutics Inc shares from India?

    You can invest in shares of Viking Therapeutics Inc (VKTX) via Vested in three simple steps:

    • Click on Sign Up or Invest in VKTX stock at the top of this page
    • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
    • Transfer USD funds to your US Brokerage account and start investing in Viking Therapeutics Inc shares
    What is Viking Therapeutics Inc 52-week high and low stock price?

    The 52-week high price of Viking Therapeutics Inc (VKTX) is $99.41. The 52-week low price of Viking Therapeutics Inc (VKTX) is $8.28.

    What is Viking Therapeutics Inc price-to-earnings (P/E) ratio?

    The price-to-earnings (P/E) ratio of Viking Therapeutics Inc (VKTX) is

    What is Viking Therapeutics Inc price-to-book (P/B) ratio?

    The price-to-book (P/B) ratio of Viking Therapeutics Inc (VKTX) is 21.71

    What is Viking Therapeutics Inc dividend yield?

    The dividend yield of Viking Therapeutics Inc (VKTX) is 0.00%

    What is the Market Cap of Viking Therapeutics Inc?

    The market capitalization of Viking Therapeutics Inc (VKTX) is $7.62B

    What is Viking Therapeutics Inc’s stock symbol?

    The stock symbol (or ticker) of Viking Therapeutics Inc is VKTX

    Feedback

    Signup to access all features and start your US investing journey!

    • Open your account in minutes
    • Take your portfolio global, starting at just $1
    Get started

    Add ticker to compare

    white-logo

    222 N. Sepulveda Blvd, Suite 10-124, 
El Segundo, CA 90245, USA

    5 Vivekanand Villa, 139 S V Road, Andheri West, Mumbai, Mumbai City, Maharashtra, India, 400058

    help@vestedfinance.co | +919513375607

    Google_Play_Store
    Apple_store
    instagram twitter linkedin

    Company

    Explore Products

    MOST POPULAR ON VESTED

    Popular US Stocks 1

    Apple Microsoft Alphabet (Google) Amazon NVIDIA Meta Platforms (Facebook) Berkshire Hathaway Tesla Eli Lilly Visa UnitedHealth Walmart JPMorgan Chase Exxon Mobil Broadcom Johnson & Johnson Mastercard Procter & Gamble Oracle Home Depot Chevron Adobe Merck Costco AbbVie

    Popular US ETFs 2

    SPDR S&P 500 ETF Trust iShares Core S&P 500 ETF Vanguard S&P 500 ETF Vanguard Total Stock Market ETF Invesco QQQ Trust Series I Vanguard FTSE Developed Markets ETF Vanguard Value ETF Vanguard Total Bond Market ETF iShares Core MSCI EAFE ETF iShares Core U.S. Aggregate Bond ETF Vanguard Growth ETF iShares Russell 1000 Growth ETF Vanguard FTSE Emerging Markets ETF iShares Core MSCI Emerging Markets ETF iShares Core S&P Mid-Cap ETF Vanguard Dividend Appreciation ETF iShares Core S&P Small-Cap ETF SPDR Gold Shares Vanguard Total International Stock ETF Vanguard Total International Bond ETF Vanguard Mid-Cap ETF Vanguard Information Technology ETF iShares Russell 2000 ETF Technology Select Sector SPDR ETF iShares Russell 1000 Value ETF

    Curated Portfolios (Vests)

    Moat Bitcoin Vest SAAS Multi-Asset Class - Aggressive Multi-Asset Class - Moderate Multi-Asset Class - Conservative Digital Cash Deglobalization Vest BlackRock Smart Beta Aging Vest Swensen Portfolio All Weather

    Others

    Calculators Terms and conditions Privacy Policy Everything Legal
    • 1Top 25 as per Marketwatch
    • 2Top 10 US Stocks from S&P 500 index as per market capitalization
    • 1Total number of KYCed accounts on Vested as of November 2023
    • 2The above portfolio is not meant to represent any real person's portfolio or a suggested portfolio but to show what a typically diversified portfolio might look like
    • 3US Stocks and ETFs are powered by VF Securities, Inc (Member FINRA/SIPC)

    Risk Disclosure - US Markets

    Global

    Vested Finance Inc. is an investment adviser in California. Vested Finance Inc. is registered with the Securities and Exchange Commission (SEC). Registration of an investment adviser dVested Finance Inc. is an investment adviser in California. Vested Finance Inc. is registered with the Securities and Exchange Commission (SEC). Registration of an investment adviser does not imply any specific level of skill or training and does not constitute an endorsement of the firm by the Commission. Vested Finance Inc. only transacts business in states in which it is properly registered or is excluded or exempted from registration. A copy of Vested Finance Inc.’s current written disclosure brochure filed with the SEC which discusses among other things, Vested Finance Inc.’s business practices, services and fees, is available through the SEC’s website at: www.adviserinfo.sec.gov. You can also find a copy of our customer relationship summary (Form CRS) here.

    All securities are offered through VF Securities, Inc. (member FINRA/SIPC). More information about this firm can be found at www.brokercheck.finra.org and at SIPC.org. This website is maintained and published by Vested Finance Inc. Vested Finance Inc., VF Securities Inc., and Vested Private Services Limited are wholly owned subsidiaries of Vested Holding Corp., referred to herein as Vested Group. You can learn more about VF Securities, Inc. on FINRA’s Broker.… Read more

    All investing carries risk. Past performance is not indicative of future returns, which may vary. Investments in stocks and Exchange Traded Funds (“ETFs”) may decline in value. Online trading has inherent risk due to system response and access times that may be affected by various factors, including but not limited to market conditions and system performance. An investor should understand such facts before trading. The risks associated with investing in international securities [including US-listed American Depositary Receipts (“ADRs”) and ETFs that contain non-US securities include, among others, country/political risk relating to the government in the home country; exchange rate risk if the country’s currency is devalued; and inflationary/purchasing power risks if the currency of the home country becomes less valuable as the general level of prices for goods and services rises.

    The information and services provided on this website are not provided to and may not be used by any person or entity in any jurisdiction where the provision or use thereof would be contrary to applicable laws, rules or regulations of any governmental authority or regulatory or self-regulatory organization or where Vested Group is not authorized to provide such information or services.

    All information published on this website is for informational purposes only and no part of it must be construed as an offer to sell or buy a security.

    No information published on the website is intended to be investment advice, portfolio management or as any form of research analysis, directly or indirectly. Each DIY Vest is created by individual users of this website, and Vested Group does not have any role in the selection of stocks for DIY Vests. The users of the website shall be solely responsible for any action taken by them pursuant to the information contained herein, including any investment decision with respect to transaction in securities for which a platform is made available on this website.

    Vested Group makes no warranty or representation, either express or implied, on any product or service offered through its website/platform. Vested Group shall not be liable in any manner whatsoever for any damage or loss, whatsoever caused, in connection with the services provided on this website/platform. Hyperlinks or external websites which may be accessed through this website, if any, are for the user’s convenience and Vested Group does not take any responsibility for the same. Any description of, reference to, or links to other products, publications or services does not constitute an endorsement, authorization, solicitation, advertisement, sponsorship by or affiliation with Vested Group with respect to any linked site or its sponsor, unless expressly stated by Vested Group. While reasonable care has been exercised to ensure that the information published on this website is adequate and reliable, no representation is made by Vested Group as to its accuracy, completeness, or fitness for any purpose and Vested Group, its affiliates, subsidiaries, and employees accept no liability of whatsoever nature for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this information.

    Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investors’ sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor.

    Read less

    Risk Disclosure - Indian Markets

    india

    P2P lending and INR Bonds are offered through Vested Services Private Limited. Such investments are subject to risks including loss of principal.

    If you have any questions about this disclaimer or in relation to information and services provided through this website, please contact us at help@vestedfinance.co / +919513375607 while providing your contact details for us to correspond further, if required. We welcome your questions and suggestions about us.

     

    By using our website, you agree to our terms and privacy policy.

    Scroll to Top